



AVID RADIOPHARMACEUTICALS TO PRESENT AT OPPENHEIMER 20TH ANNUAL HEALTHCARE CONFERENCE ON NOVEMBER 3RD

Leader in development of molecular imaging compounds to present clinical trial advances for Alzheimer's Disease, Parkinson's Disease and Diabetes

Philadelphia, PA, October 27, 2009 – [Avid Radiopharmaceuticals, Inc.](#), a leader in the development of products with the potential for earlier and more effective detection, diagnosis and monitoring of brain disorders, today announced that [Daniel M. Skovronsky](#), M.D., Ph.D., Founder and CEO, will present at the [Oppenheimer 20th Annual Healthcare Conference](#) on Tuesday, November 3, 2009 at 1:00pm ET in the Louis XVI Room at the Waldorf=Astoria in New York, NY.

Dr. Skovronsky will present an update on Phase III clinical trials and the timeline towards commercialization for the company's amyloid imaging compound ¹⁸F-AV-45 (AV-45), the most advanced F-18 compound in development for imaging amyloid plaque in the brain associated with Alzheimer's disease. Avid's AV-45 was the first amyloid imaging compound to enter multi-center, IND-approved, clinical studies in the U.S., and has now been studied in more than 600 individuals, ranging from cognitively normal individuals to those with Alzheimer's disease. AV-45 entered a pivotal registration study earlier this year using a unique trial design that was based upon recommendations by the FDA peripheral and CNS advisory committee in October 2008.

Avid's second program, ¹⁸F-AV-133 (AV-133) PET imaging of the vesicular monoamine transporter 2 (VMAT2) in patients with suspected dopaminergic degeneration, is currently in Phase II clinical trials. AV-133 has also been shown to be a marker for beta cells of the pancreas in preclinical studies. The compound is now in Phase I studies to test the ability of this molecular imaging agent to distinguish type 1 and type 2 diabetes subjects from healthy normal individuals based on a PET scan of the pancreas.

About the Oppenheimer 20th Annual Healthcare Conference

The conference will present a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries. Companies participating in this conference will address topical issues such as health reform, Medicare and Medicaid, generic drug regulation, development of new blockbuster pharmaceutical and biotechnology products, product safety and patent issues, cross-border re-importation, Food and Drug Administration policy, managed care, and the current M&A environment.

About Avid Radiopharmaceuticals, Inc.

Avid Radiopharmaceuticals is a leader in the development of molecular imaging products with the potential for earlier and more effective detection, diagnosis and monitoring of major chronic human diseases. Based in Philadelphia, PA, the company is a pioneer in the development of molecular imaging agents for Alzheimer's disease that could lead to earlier diagnosis and better evaluation of drugs designed to prevent or reverse amyloid plaque build-up in the brain. Avid is currently conducting Phase III clinical studies of ¹⁸F-AV-45 for imaging amyloid plaques in Alzheimer's disease, and is in Phase I and II trials with ¹⁸F-AV-133 for imaging the vesicular monoamine transporter (VMAT2) in diseases involving dopaminergic degeneration (Parkinson's disease and Dementia with Lewy Bodies) and beta cell dysfunction (Type I and Type II Diabetes Mellitus). For more information, please visit www.avidrp.com.

CONTACT:

Richard A. Baron
Chief Financial Officer
baron@avidrp.com
215-298-0723

###